TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.

Дата публикации: 20-11-2025 12:00:00

TESARO, Inc., confirms it has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation	0	8.67	27-04-2026
2	GSK completes acquisition of RAPT Therapeutics	0	4.05	03-03-2026
3	GSK enters agreement to acquire RAPT Therapeutics	0	8.62	20-01-2026
4	GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences	0	13.32	15-09-2026
5	GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	0	9.8	11-05-2026
6	GSK and Alfasigma announce agreement on worldwide rights for linerixibat	0	5.1	09-03-2026
7	GSK completes acquisition of 35Pharma Inc.	0	3.99	15-04-2026
8	GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China	0	11.6	28-07-2026
9	АО «Гипростроймост» требует с тульской АО «КРТО» 1,78 млн рублей	0	8.43	27-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 5.62. Источник: www.gsk.com.